Pages that link to "Q37412918"

The following pages link to Oral phosphate binders (Q37412918):

Displaying 43 items.

• Phosphate binders for preventing and treating bone disease in chronic kidney disease patients (Q24234036) (← links)
• Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data (Q30854189) (← links)
• Phosphate and carbonate salts of calcium support robust bone building in osteoporosis (Q33908656) (← links)
• Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum (Q34421007) (← links)
• Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China (Q34573734) (← links)
• Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. (Q35030613) (← links)
• Evaluation of intestinal phosphate binding to improve the safety profile of oral sodium phosphate bowel cleansing (Q35196150) (← links)
• Sigmoid colon diverticula perforation associated with sevelamer hydrochloride administration: A case report (Q37171642) (← links)
• Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease (Q37620347) (← links)
• Phosphate binders in CKD: chalking out the differences. (Q37629694) (← links)
• New therapies: calcimimetics, phosphate binders and vitamin D receptor activators. (Q37691299) (← links)
• Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III – V) (Q37803240) (← links)
• Pharmacotherapy and interventional treatments for secondary hyperparathyroidism: current therapy and future challenges (Q37807991) (← links)
• Uraemic vasculopathy in children with chronic kidney disease: prevention or damage limitation? (Q37809763) (← links)
• Sensing mechanisms involved in Ca2 and Mg2 homeostasis. (Q38012604) (← links)
• Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia (Q38029196) (← links)
• Update and critical appraisal of sevelamer in the management of chronic renal failure (Q38160473) (← links)
• Contemporary management of phosphorus retention in chronic kidney disease: a review (Q38511621) (← links)
• Use of magnesium as a drug in chronic kidney disease (Q38526304) (← links)
• Novel iron-containing phosphate binders for treatment of hyperphosphatemia (Q38570622) (← links)
• Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo (Q38892733) (← links)
• Phosphate Binders and Targets Over Decades: Do We have it Right Now? (Q39033792) (← links)
• PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure (Q41007103) (← links)
• An unusual hurdle to renal transplantation: speckled abdominal opacities induced by lanthanum carbonate (Q42755557) (← links)
• Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients (Q42918576) (← links)
• Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia (Q44471363) (← links)
• One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis. (Q46034498) (← links)
• Nurse-led education and counselling to enhance adherence to phosphate binders. (Q46103271) (← links)
• Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease (Q46169005) (← links)
• Cost-Effectiveness of Lanthanum Carbonate versus Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Patients with End-Stage Renal Disease: A US Payer Perspective (Q46242175) (← links)
• Adherence to phosphate binders in hemodialysis patients: prevalence and determinants. (Q47606470) (← links)
• Azulene-Based Macrocyclic Receptors for Recognition and Sensing of Phosphate Anions (Q48277863) (← links)
• Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats. (Q48951447) (← links)
• Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide (Q51743408) (← links)
• Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. (Q53242888) (← links)
• Lanthanum chloride bidirectionally influences calcification in bovine vascular smooth muscle cells (Q57218681) (← links)
• Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study) (Q57218844) (← links)
• Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients (Q57220069) (← links)
• Iron uptake and ferrokinetics in healthy male subjects of an iron-based oral phosphate binder (SBR759) labeled with the stable isotope 58Fe (Q57695687) (← links)
• Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate (Q57798939) (← links)
• Use of phosphate-binders and risk of infection-related and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort Study. (Q64956810) (← links)
• Can aluminum‐based binders be used safely? (Q84620313) (← links)
• Novel phosphate binders: plus ça change, plus c'est la même chose (Q85208482) (← links)